R-Ketamine Composition for Rapid Antidepressant Effect With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants are ineffective for treatment-resistant psychiatric diseases such as depression, bipolar disorder, obsessive-compulsive disorder, and PTSD, with ketamine having significant side effects and being a controlled substance, limiting its clinical use.
Innovation Solution
Development of R-ketamine, which has lower affinity for the NMDA receptor and fewer side effects, providing rapid and long-lasting antidepressant effects without the psychotomimetic effects of S-ketamine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ketamine is used for treatment of treatment-resistant depression, then rapid and robust antidepressant effects are achieved, but psychotomimetic side effects and drug dependence occur
Solution Approach 1:
The racemic ketamine molecule is segmented into its two enantiomeric components: R-ketamine and S-ketamine. The patent isolates and utilizes only the R-enantiomer, which provides antidepressant effects without the psychotomimetic side effects associated with the S-enantiomer. This segmentation allows selective application of the beneficial component while eliminating the harmful component.
Solution Approach 2:
The harmful S-ketamine component is extracted and removed from the therapeutic mixture. The patent specifically uses R-ketamine or R-ketamine-enriched compositions that are substantially free of S-ketamine, thereby extracting only the therapeutic element while leaving behind the harmful element that causes psychotomimetic effects and dependence.
2Reliability
If current antidepressants are used for treatment, then they are effective for some patients, but treatment-resistant patients show no response and require several weeks to express drug efficacy
Solution Approach 1:
R-ketamine acts rapidly on the NMDA receptor to initiate antidepressant effects without requiring the prolonged adaptation period needed by conventional antidepressants. The preliminary action of R-ketamine on glutamatergic transmission provides immediate therapeutic benefit, bypassing the weeks-long delay characteristic of traditional antidepressant mechanisms.
3Reliability
If dose of antidepressant is increased to achieve remission, then therapeutic effects improve, but patient suffers from various side effects
Solution Approach 1:
By segmenting ketamine into its enantiomeric components and selecting only the R-enantiomer, the patent achieves therapeutic effectiveness at lower doses without the dose-dependent side effects that plague conventional antidepressants. The R-enantiomer provides the desired therapeutic action with a cleaner safety profile.
Solution Approach 2:
The patent changes the chemical parameter of the ketamine molecule by selecting a specific enantiomer (R-ketamine) with different pharmacological properties than the S-enantiomer. This parameter change results in a compound that maintains antidepressant efficacy while reducing harmful side effects, avoiding the need to increase dose and thereby avoiding dose-related adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
R-ketamine exhibits potent and sustained antidepressant effects with reduced side effects, making it a promising therapeutic option for treatment-resistant psychiatric diseases.
Implementation Method 1
R-ketamine or a pharmaceutically acceptable salt thereof... substantially free of S-ketamine... NMDA receptor antagonist ketamine exhibits rapid and robust antidepressant effects
Data Source
AI summary
Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.